Literature DB >> 26166234

N,N-Dimethyltryptamine-Induced Psychosis.

Neil E Paterson1, W Connor Darby, Preetpal S Sandhu.   

Abstract

BACKGROUND: N,N-dimethyltryptamine (DMT) is a 5-hydroxytryptamine 2A and 1A receptor agonist that exhibits potent psychoactive properties in humans. Recreational use of this drug has increased precipitously and is likely to result in an increase in patients presenting with substance-induced psychoses. The present case provides an early example of substance-induced psychosis attributable to repeated use of DMT. CASE: A 42-year-old white man, with no significant past psychiatric history, was brought to the emergency department by the police and was found to exhibit disinhibited behavior, elevated affect, disorganized thought process, and delusions of reference. Laboratory studies revealed elevated creatinine kinase level indicative of rhabdomyolysis. The patient endorsed recent and repeated use of DMT, as well as long-term Cannabis (marijuana) use. Over the course of the next 3 weeks, the patient was successfully treated with quetiapine for psychosis, divalproex sodium (Depakote) for impulsivity, gabapentin for anxiety, and hydroxyzine for sleep, which resulted in the resolution of his symptoms and development of reasonable insight and judgment. Approximately 6 months after discharge, the patient remained treatment compliant, as well as drug and symptom free.
CONCLUSIONS: This case report illustrates an important example of substance-induced psychosis that resolved with antipsychotic treatment in a 42-year-old white man with no past psychiatric history likely attributable to the use of DMT. Given the increasing use of this substance, the emergency department, primary care, and inpatient services are likely to see a significant increase in similar cases.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26166234     DOI: 10.1097/WNF.0000000000000078

Source DB:  PubMed          Journal:  Clin Neuropharmacol        ISSN: 0362-5664            Impact factor:   1.592


  6 in total

1.  [Ayahuasca-induced psychosis in a patient with bipolar disorder].

Authors:  Nicolas Zellner; Tobias Zellner; Jan Warninghoff
Journal:  Nervenarzt       Date:  2019-11       Impact factor: 1.214

2.  Ayahuasca: An ancient sacrament for treatment of contemporary psychiatric illness?

Authors:  Benjamin J Malcolm; Kelly C Lee
Journal:  Ment Health Clin       Date:  2018-03-23

Review 3.  Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies.

Authors:  Rafael G Dos Santos; José Carlos Bouso; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2017-02-23

Review 4.  Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.

Authors:  Jonathan Hamill; Jaime Hallak; Serdar M Dursun; Glen Baker
Journal:  Curr Neuropharmacol       Date:  2019       Impact factor: 7.363

Review 5.  Toxicology and Analysis of Psychoactive Tryptamines.

Authors:  Sara Malaca; Alfredo Fabrizio Lo Faro; Alice Tamborra; Simona Pichini; Francesco Paolo Busardò; Marilyn A Huestis
Journal:  Int J Mol Sci       Date:  2020-12-04       Impact factor: 5.923

Review 6.  Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders.

Authors:  Henry Lowe; Ngeh Toyang; Blair Steele; Justin Grant; Amza Ali; Lorenzo Gordon; Wilfred Ngwa
Journal:  Molecules       Date:  2022-04-14       Impact factor: 4.927

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.